Ticagrelor is the first of a new class of drugs, known as cyclopentyltriazolopyrimidines, that also inhibit platelet aggregation by binding to the P2Y12 inhibitor [187, 188]. However, there are key differences in terms of its metabolism and mechanism of effect, leading to a drug profile disti...
145 patients with AF and with broader indications for anticoagulation (paired with development of safer agents), combination of NOAC with a P2Y12 inhibitor is likely to be the favoured strategy. 11.4.4 Elderly Patients For many of the reasons previously outlined (high bleeding risk, concerns ...